Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk

S-C Hung1,2, S-W Lai3,4, P-Y Tsai2,5, P-C Chen2,3, H-C Wu3,6, W-H Lin7 and F-C Sung*,2,5

1Department of Emergency Medicine, Nantou Hospital, Nantou, Taiwan; 2Department of Public Health, China Medical University, Taichung, Taiwan; 3School of Medicine, China Medical University, Taichung, Taiwan; 4Division of Family Medicine, China Medical University Hospital, Taichung, Taiwan; 5Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan; 6Division of Urology, China Medical University Hospital, Taichung, Taiwan and 7Department of Urology, Nantou Hospital, Nantou, Taiwan

Background: The incidence of prostate cancer is much lower in Asian men than in Western men. This study investigated whether prostate cancer is associated with prostatitis, benign prostatic hyperplasia (BPH), and other medical conditions in the low-incidence population.

Methods: From the claims data obtained from the universal National Health Insurance of Taiwan, we identified 1184 patients with prostate cancer diagnosed from 1997 to 2008. Controls comprised 4736 men randomly selected from a cancer-free population. Both groups were 50 years of age or above. Medical histories between the two groups were compared.

Results: Multivariate logistic regression analysis showed that prostatitis and BPH had stronger association with prostate cancer than the other medical conditions tested. Compared with men without prostatitis and BPH, a higher odds ratio (OR) for prostate cancer was associated with BPH (26.2, 95% confidence interval (CI) 20.8–33.0) than with prostatitis (10.5, 95% CI = 3.36–32.7). Men with both conditions had an OR of 49.2 (95% CI = 34.7–69.9).

Conclusion: Men with prostate cancer have strong association with prostatitis and/or BPH. Prostatitis interacts with BPH, resulting in higher estimated relative risk of prostate cancer in men suffering from both conditions.

Prostate cancer is the most common cancer that affects men in Western countries, particularly in the United States (Klein et al, 2007; Jemal et al, 2009, 2010). The incidence and prevalence of prostate cancer in the United States have continuously increased since the introduction of prostate-specific antigen (PSA) screen test in 1992. Among the 217 730 new cases estimated in 2010, prostate cancer accounted for 28% of all cancers in American men. This cancer was also responsible for 22.2% (n = 382 000) of cancers that affected men in 40 European countries in 2008 (Ferlay et al, 2010) and 31.2% (n = 19 403) of cancers in Australian men in 2007 (Australian Institute of Health and Welfare and; Australasian Association of Cancer Registries (2010)). Although the incidence is much lower in Asian men than in Western men, the incidence rate of prostate cancer has continuously increased in recent decades (Pu et al, 2004). According to the Taiwan Cancer Registry Report, the incidence of prostate cancer increased from 7.5/100 000 in 1992 to 23.5/100 000 in 2007 (Taiwan Cancer Registry, 2010). Furthermore, the clinical outcome of localised prostate cancer post-radical prostatectomy has been unsatisfactory, and mortality due to prostate cancer is increasing in Taiwan (Huang et al, 2010; Tseng, 2011).

Relatively little is known about the risk factors associated with the increasing trend of prostate cancer in Asian men, other than the fact that prostate cancer is highly related to aging, ethnicity,
and family history of prostate cancer (Hsing and Chokkalingam, 2006; Klein et al., 2007). Much attention has recently been given to the roles of chronic inflammation and infection in the pathogenesis and progression of prostate cancer (Kramer et al., 2007; Drake, 2010; De Nunzio et al., 2011). The literature has suggested the association between prostatitis, benign prostatic hyperplasia (BPH), and prostate cancer. Van Vuuren et al. (2012) considered prostatitis as an early sign of cancer for men with adenocarcinoma of the prostate. Components of metabolic syndromes and BPH are also strongly related to aging (Klein et al., 2007). These metabolic syndromes may contribute to the development of BPH and clinical prostate cancer (Hammarsten and Hogstedt, 2002). Prostate cancer screening in symptomatic BPH patients is, therefore, of great concern for men, particularly when the alternative therapies used do not involve tissue pathological analysis (Hall et al., 1996).

The results of studies on the risk of prostate cancer associated with prostatitis and BPH using population-based data remain inconclusive. In particular, studies on this association are limited for Asian men. We suspect that the mechanism through which prostatitis and BPH contribute to prostate cancer in Asian men is different from Western men, primarily because the incidence of the said cancer type is much rarer in Asian men (Pu et al., 2004; Taiwan Cancer Registry, 2010). Using a population-based data set with information on the medical conditions available for men with low cancer incidence to investigate the said mechanisms can aid in clarifying the association between prostate cancer and prostatitis and BPH. We, therefore, used the data from universal insurance claims to investigate whether prostatitis and BPH contribute to the risk of prostate cancer in Taiwanese men. In addition to BPH and prostatitis, this study also explored comorbidities that may be associated with the risk of prostate cancer.

**MATERIALS AND METHODS**

**Data sources.** This study used the 1996–2008 reimbursement claims submitted to the National Health Insurance programme, a universal insurance system established by the Bureau of National Health Insurance of the Department of Health in Taiwan. This insurance programme has covered 99% of the population since 1999 (Cheng, 2003). The data set consisted of claims from 1 million people randomly selected from a total of 23 million insured individuals based on the year 2000 population. In these claims, information on socio-demographic status was available, in addition to health care visits of in-patients and out-patients, from 1996 to 2008. The electronic data files were obtained from the National Health Research Institutes. The identification numbers of all the patients were scrambled to ensure patient confidentiality. This study was, therefore, exempted from full institutional review. We used the International Codes of Diseases 9th Revision, Clinical Modification (ICD-9-CM) to identify diseases.

**Study subjects.** We identified men aged 50 years and above with primary prostate cancer (ICD-9-CM 185 or A-code A124) diagnosed during the period of 1997–2008 as the sample population. For each prostate cancer patient, four controls comprising cancer-free men at the age of 50 and above were randomly selected from the same data set within the same time period. The age of a study subject was defined according to the date when the patient was diagnosed with prostate cancer or when the control was selected. To explore the potential comorbidities associated with increased risk of prostate cancer, we screened the medical history to search for comorbidities that existed before the identification of the study subjects. Metabolism syndrome and infection have been previously studied as risk factors associated with prostate cancer (Hammarsten and Hogstedt, 2002; Kramer et al., 2007; Drake, 2010; De Nunzio et al., 2011; Taylor et al., 2005). Comorbidities including diabetes mellitus (ICD-9-CM 250 or A-code A181), hypertension (ICD-9-CM 401-405 or A-code A182), hyperlipidemia (ICD-9-CM 272 or A-code A182), prostatitis (ICD-9-CM 601.X), testitis and epididymitis (604.X), gonorrhoea and chlamydia infection (ICD-9-CM 098.X, 099.X), BPH (ICD-9-CM 600.X or A-code A360), and obesity (ICD-9-CM 278.00, 278.01 or A-code A183) were included as covariates in this study.

**Table 1. Comparison of baseline characteristics between prostate cancer cases and cancer-free controls**

| Age group (years) | Total, N = 5920 | Yes, N = 1184 |
|-------------------|----------------|--------------|
|                   | N   | % |        | N   | % |        | P-value*     |
| 50–64             | 2765 | 46.7 | 2611 | 55.1 | 154 | 13.0 | <0.0001     |
| 65–74             | 1610 | 27.2 | 1162 | 24.5 | 448 | 37.8 |            |
| ≥75               | 1545 | 26.1 | 963  | 20.3 | 582 | 49.2 |            |
| Mean (s.d.)       | 66.9 | (11.4) | 65.0 | (11.4) | 74.4 | (8.1) | <0.0001     |

**Comorbidity and medication**

| Comorbidity and medication | Total, N = 5920 | Yes, N = 1184 |
|---------------------------|----------------|--------------|
|                           | N   | % |        | N   | % |        | P-value*     |
| Diabetes mellitus         | 704 | 11.9 | 530  | 11.2 | 174 | 14.7 | 0.0009      |
| Hypertension              | 2739 | 46.3 | 1951 | 41.2 | 788 | 66.6 | <0.0001     |
| Hyperlipidemia            | 1217 | 20.6 | 869  | 18.4 | 348 | 29.4 | <0.0001     |
| Prostatitis               | 236 | 3.99 | 99   | 2.09 | 137 | 11.6 | <0.0001     |
| Testitis and epididymitis | 48 | 0.81 | 31   | 0.65 | 17 | 1.44 | 0.007       |
| Gonorrhoea and chlamydia infection | 16 | 0.27 | 11 | 0.23 | 5 | 0.42 | 0.26 |
| Benign prostatic hyperplasia | 2155 | 36.4 | 1071 | 22.6 | 1084 | 91.6 | <0.0001     |
| Obesity                   | 17 | 0.29 | 11 | 0.23 | 6 | 0.51 | 0.11 |

*P-value comparing patients with and without prostate cancer.
*Comorbidities: enrolled diagnosis criterion for hypertension and hyperlipidemia is visited the clinic at least three times; for diabetes mellitus (DM), at least twice per year with anti-DM medication; for other comorbidities, at least two times.
Statistical analysis. In the data analysis, we first compared the distributions of age and comorbidities between cases and controls. Chi-squared and t-test were used to compare differences between cases and controls for categorical variables and continuous variables, respectively. The significant variables were further included in the multivariate logistic regression analysis to measure the odds ratio (OR) at 95% confidence interval (CI) for the prostate cancer-associated covariates. Data analysis further verified the role of the interaction between prostatitis and BPH in the development of prostate cancer. All tests were two-tailed, and a P-value < 0.05 was considered to indicate statistical significance. Statistical analyses were performed using the statistical package SAS for Windows (version 9.1 SAS Institute Inc., Cary, NC, USA).

RESULTS

This study consisted of 1184 prostate cancer cases and 4736 cancer-free controls. Cases were ~10 years older than controls, as suggested by the mean age (P < 0.0001) (Table 1). Compared with the controls, cases were more prone to diabetes (14.7% vs 11.2%), hypertension (66.6% vs 41.2%), hyperlipidemia (29.4% vs 18.4%), prostatitis (11.6% vs 2.09%), testisitis and epididymitis (1.44% vs 0.65%), and BPH (91.6% vs 22.6%).

In the multivariate logistic regression model, compared with the 50- to 64-year-old age group, older patients were at higher odds of prostate cancer, with an OR of 3.05 (95% CI = 2.43–3.83) for the 65–74-year-old age group, and 3.97 (95% CI = 3.16–4.98) for the ≥75-year-old age group (Table 2). Among comorbidities, a high estimated relative risk for prostate cancer was observed in men with prostatitis (OR = 9.77, 95% CI = 3.09–30.9) and BPH (OR = 24.9, 95% CI = 19.8–31.4). The interaction term of prostatitis ∗ BPH was also significant with an OR of 5.17 (95% CI = 1.58–17.0).

Table 3 shows the results of the stratified analysis for the demonstration of the interaction between prostatitis and BPH in predicting prostate cancer. Compared with patients without both prostatitis and BPH, patients with history of both diseases were at the highest odds for prostate cancer development, with adjusted OR of 49.2 (95% CI = 34.7–69.9). BPH (OR = 26.2, 95% CI = 20.8–33.0) was also found to have a much stronger association with prostate cancer than prostatitis (OR = 10.5, 95% CI = 3.36–32.7).

DISCUSSION

Based on the data set in this study, the calculated average incidence of prostate cancer was 19.7/100,000 for men aged 50 years and above from 1997 to 2008 in Taiwan (data not shown), which was in agreement with the incidence trend officially reported by the Taiwan Cancer Registry, namely, 7.5–23.5/100,000 in 1992–2007 (Taiwan Cancer Registry, 2010). A decline of prostate cancer incidence was noted in the United States and in some European countries, but not in Taiwan (Bray et al, 2010). Some studies have suggested that the trend of prostate cancer incidence is mainly affected by the availability of PSA testing and screening programs. No regular extensive PSA screening programme existed in Taiwan before the reformation of the universal health insurance programme. This test has become easily available for men as part of the national health insurance routine checkup since 1996, particularly for men who complain about low urinary track symptoms. The persisting elevated incidence of prostate cancer and the possible risk associated with it should not be ignored.

In this study, age was found to be highly related to the incidence of prostate cancer. The prevalence of metabolic syndromes is also related to age. To determine the relationship between prostate cancer and other comorbidities, we investigated the metabolic syndromes available in the data of the reimbursement claims. The relationships between prostate cancer, obesity, and metabolic syndromes were at the highest odds for prostate cancer development, with adjusted OR of 49.2 (95% CI = 34.7–69.9). BPH (OR = 26.2, 95% CI = 20.8–33.0) was also found to have a much stronger association with prostate cancer than prostatitis (OR = 10.5, 95% CI = 3.36–32.7).
Chronic inflammation is commonly associated with BPH, but not
et al

Habermacher

et al

tion prostatitis (Krieger

et al

Category III comprising chronic prostatitis/chronic pelvic pain

account for 90% of diagnosed cases (Krieger

et al

African-American and 7.3% in

Caucasian men (Pettaway

et al

With a relatively low incidence of prostate cancer, the pattern observed in this

study is much greater than that reported for Western men. An

11-year follow-up study from a single health system has recently

reported that the incidences of prostate cancer are 9% in men

with BPH, including 14.3% in African-American and 7.3% in

Caucasian men (Pettaway

et al

In the present study, BPH

was found to be strongly associated with prostate cancer in the

logistic regression model after normalising the age and other

covariates. However, we were unable to identify the site at which

the prostate cancer developed from the claims data. Selection bias

might also exist, especially in patients who received transurethral

retrograde prostatectomy (TURP) for BPH. Prostate cancers can be

found in 4–15% of the surgical histology samples, with or without

previous clinical suspicion (Delgadoeva

et al

2010). However, the

strong association between BPH and prostate cancer may diminish

little even if the cases identified by TURP are excluded.

Inflammation is another important factor contributing to cancer

progression. Chronic inflammatory conditions are associated with

cancer development, such as reflux esophagitis with oesophageal

cancer and virus hepatitis with hepatocellular carcinoma. The

hypothesis about chronic inflammation inducing carcinogenesis is

based on the local irritation associated with the regulation of the

inflammatory cells and cytokine (Cousens and Werb, 2002). Both

bacteria- and non-bacteria-related prostatitis are, but not sexually

transmitted diseases (STDs), significant factors associated with

prostate cancer. However, the causality remains unclear (Dennis

et al

2002; Roberts

et al

2004).

Based on six population-based case–control studies and five

hospital-based case–control studies, an earlier meta-analysis found

a 1.6-fold increased risk of prostate cancer for men with a

prostatitis history (Dennis

et al

2002). Studies also found that

STDs are potentially associated with increased risk of prostate

cancer (Dennis

et al

2002; Taylor

et al

2005). However, the

selecting bias and recall bias about the history of prostatitis are

concerned in epidemiological studies. Prostatitis could be cate-

gorised into four groups: category I comprising acute bacteria

prostatitis, category II comprising chronic bacterial prostatitis,

category III comprising chronic prostatitis/chronic pelvic pain

syndrome, and category IV comprising asymptomatic inflamma-

tion prostatitis (Krieger

et al

1999). Category III prostatitis may

account for 90% of diagnosed cases (Krieger

et al

1999), and

patients with category IV prostatitis are usually cases that are

accidently diagnosed (Habermacher

et al

2006). Delongchamps

et al

2008) evaluated 167 autopsied prostates and found that

chronic inflammation is commonly associated with BPH, but not

the cancer. However, the sample size was probably too small to

identify a significant relationship. They found that chronic

inflammatory infiltrations are mostly located in the transitional

zones instead of the peripheral zone where prostate cancer is

usually diagnosed (McNeal

et al

1988; Pavelic and Zeljko, 2002).

These pathological findings are valuable for further studies.

However, the autopsied findings may not truly reflect the entire

past exposure history of prostatitis.

In the present study, patients with prostatitis history may have

increased risk of prostate cancer, but not patients with testitis and

epididymitis, as well as those with gonorrhoea and chlamydia

infection. This result suggests that the localised inflammation effect

may have a more important role in carcinogenesis. Compared with

previous self-report case–control studies, the high-coverage claims

data set may be more reliable in exploring the history of prostatitis

and STDs.

Studies have focused on the contribution of inflammation to

both BPH and prostate cancer (Alcaraz

et al

2009; De Nunzio

et al

2011). Case–control studies have linked BPH to the risk of prostate

cancer for Saudi Arabian men who also have low incidence of the

disease (Mosli

2003; Abdel-Meguid

et al

2009; Alcaraz

et al

2009). Chronic inflammation is associated with BPH and prostate

cancer based on medical records and needle biopsy findings (Mosli,

2003; Abdel-Meguid

et al

2009). However, the magnitude of the

relationship among these three disorders was not well clarified

(ABdel-Meguid

et al

2009).

Our population-based study proved that prostate cancer is

associated with prostatitis and BPH. Benign prostatic hyperplasia is

a much stronger risk factor than prostatitis in terms of cancer

association. Overlap in BPH and prostatitis exists in our study.

Patients with prostatitis are more likely to overlap with BPH in

cancer cases than in controls (97.1% vs

16.2%), indicating high linearity between prostatitis and BPH. A strong interaction

between prostatitis and BPH for predicting prostate cancer

thus appeared in this study, which culminated with an adjusted

OR of 49.2 for men with the history of both prostatitis and

BPH. To the best of our knowledge, no previous study has reported

such a strong synergistic interaction. The causal association of

prostate cancer involving prostatitis and BPH is inconclusive in

studies done on Western men. This association in Asian men is

rather different from that in Western men. With a relatively

low incidence of prostate cancer, the pattern observed in this

study is worthy of further study. In this study, cases are 6.2-fold

more likely to have a history of both BPH and prostatitis

than controls (11.9% vs

1.92%). The irritation and stimulation

from BPH and prostatitis combined may increase the risk of

prostate cancer.

Some medications have been discussed as risk factors for

prostate cancer. We also analysed the association with medications

that were mostly studied in relation with prostate cancer (Jacobs

et al

2005). Our results showed that only aspirin exhibited a protective association in reducing the risk of prostate cancer (data not shown). This result is consistent with a large cohort study done on the use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) conducted in the United States. Jacobs

et al

2005) found that men with long-term regular use of aspirin have reduced

risk of prostate cancer (RR = 0.85, 95% CI = 0.73 to 0.99). Their recent study showed long-term regular acetaminophen use may also reduce the overall prostate cancer risk to a relative risk of 0.62 (Jacobs

et al

2011). Although acetaminophen shares the same pathway as NSAID, the anti-inflammatory effect is weak. This result may provide information for further explorations on prostate carcinogenesis.

Limitations. This study was limited by the use of data from

insurance claims because some information on lifestyle and

physical examination status are not available. Thus, we were
unable to ascertain whether prostate cancer is associated with smoking, drinking, waist measurement, and so on. Data on family history, molecular factors, and pathophysiology examinations were not available as well. However, we found that obesity is not a significant factor associated with the cancer. Patients with prostatitis and/or BPH may have higher odds to be diagnosed with prostate cancer than the controls, primarily because the former group may visit physicians more frequently. Therefore, the risk estimation for prostate cancer might be overestimated. However, the high accessibility and inexpensive national health system make our analysis more reliable. Some concerns may exist regarding the miscoding and over diagnosis of BPH and prostatitis using the claims data set. The causality of prostate cancer was not established in this study, although BPH and prostatitis were diagnosed before the diagnosis of prostate cancer. Therefore, the mechanism remains unclear.

CONCLUSIONS

Although the incidence of prostate cancer is much lower in Taiwanese men than in men from Western countries, the incidence in Taiwan is steadily increasing. Diabetes and taking aspirin may have a protective effect against prostate cancer, but their beneficial effect may be compromised by overall impairment, leading to the development of BPH and/or prostatitis. Patients with the history of BPH and/or prostatitis could have significantly increased risk of prostate cancer, which is stronger for those with BPH than those with prostatitis. The odds is much higher for patients with both BPH and prostatitis.

ACKNOWLEDGEMENTS

We would like to thank the Taiwan National Health Research Institute for providing the NH database. This study was partly supported by the National Sciences Council (Grant no. NSC 100-2621-M-039-001), the China Medical University Hospital (Grant no. 1MS1), the Taiwan Department of Health Clinical Trial and Research Centre for Excellence (Grant no. DOH100-TD-B-111-004), and the Cancer Research Centre of Excellence (DOH100-TD-C-111-005).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Abdel-Meguid TA, Mosli HA, Al-Maghrabi JA (2009) Prostate inflammation. Association with benign prostatic hyperplasia and prostate cancer. Saudi Med J 30: 1563–1567.

Alcaraz A, Hammerer P, Tubaro A, Schroder FH, Castro R (2009) Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 55: 864–873.

Australian Institute of Health and Welfare & Australasian Association of Cancer Registries (2010) Cancer in Australia: an overview. 2010. Cancer series no. 60. Cat. no. CAN 56. Canberra: AIHW. 2010.

Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46: 3040–3052.

Chang RT, Kirby R, Challacombe BJ (2012) Is there a link between BPH and prostate cancer? Practitioner 256: 13–16.

Cheng TM (2003) Taiwan’s new national health insurance program: genesis and experience so far. Health Aff (Millwood) 22: 61–76.

Cousens LM, Webz Z (2002) Inflammation and cancer. Nature 420: 860–867.

De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, Sciarra A, Tubaro A (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60: 106–117.

Dellavedova T, Ponzano R, Racca L, Minuzzi F, Dominguez M (2010) Prostate cancer as incidental finding in transurethral resection. Arch Esp Urol 63: 855–861.

DeLongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Tureta G, Jumbicel M, Haas GP (2008) Evaluation of prostatitis in autopsies:--chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 179: 1736–1740.

Denis LK, Lynch CF, Torner JC (2002) Epidemiologic association between prostatitis and prostate cancer. Urology 60: 78–83.

Drake CG (2010) Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 10: 580–593.

Feng YH, Velazquez-Torres G, Gully C, Chen J, Lee MH, Yeung SC (2011) The impact of type 2 diabetes and antiinflammatory drugs on cancer cell growth. J Cell Mol Med 15: 825–836.

Ferlay J, Parkin DM, Stelarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765–781.

Gorbachinsky I, Akpinar H, Assimos DG (2010) Metabolic syndrome and urogenic diseases. Rev Urol 12: e157–e180.

Habermacher GM, Chason JT, Schaeffer AJ (2006) Prostatitis/chronic pelvic pain syndrome. Annu Rev Med 57: 195–206.

Hall MC, Roehrborn CG, McConnell JD (1996) Is screening for prostate cancer necessary in men with symptoms of benign prostatic hyperplasia? Semin Urol Oncol 14: 122–133.

Hammarsten J, Hogstedt B (2002) Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer. Scand J Urol Nephrol 36: 330–338.

Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11: 1388–1413.

Hsing AW, Sakoda LC, Chua Jr S (2007) Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 86: s843–s857.

Huang SP, Huang CY, Liu CC, Yu CC, Pu YS, Chueh SC, Yu HJ, Wu TT, Li CC, Huang CH, Wu WJ (2010) Clinical outcome of Taiwanese men with clinically localized prostate cancer post-radical prostatectomy: a comparison with other ethnic groups. Aging Male 13: 10–17.

Jacobs EJ, Newton CC, Stevens VL, Garstur SM (2011) A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol Biomarkers Prev 20: 1322–1328.

Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ (2005) A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97: 975–980.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59: 225–249.

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60: 277–300.

Klein EA, Platz EA, Thompson DM (2007) Etiology, and prevention of prostate cancer. In Campbell-Walsh Urology, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds), 9 edn. pp 2854–2873. Saunders Elsevier: Philadelphia, PA, USA.

Kramer G, Mitteregger D, Marberger M (2007) Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European urology 51: 1202–1216.

Krieger JN, Nyberg Jr L, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282: 236–237.

McNeil JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostastic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 12: 897–906.

Mosli HA (2003) Prostate cancer in Saudi Arabia in 2002. Saudi Med J 24: 573–581.

Pavelic J, Zelkzo Z (2002) [Prostate gland-transition zone lesions. Etiology, direction of spread. Am J Surg Pathol 12: 897–906.].

Petway CA, Lamerato LE, Eddy MT, Edwards JK, Hogue SL, Crane MM (2011) Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence. BJU Int 108: 1302–1308.

Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH, Chen J (2004) Changing trends of prostate cancer in Asia. Aging Male 7: 120–132.

Roberts RO, Bergstralh EJ, Bass SE, Lieber MM, Jacobsen SJ (2004) Prostatitis as a risk factor for prostate cancer. Epidemiology 15: 93–99.
Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhaus ML, Lin DW, White E, Thompson IM (2011) Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. *Am J Epidemiol* **173**: 1419–1428.

Taiwan Cancer Registry (2010) Cancer Incidence in Taiwan (accessed 29 March 2010). Available at http://tcr.cph.ntu.edu.tw/main.php?page=A5.

Taylor ML, Mainous AG III, Wells BJ (2005) Prostate cancer and sexually transmitted diseases: a meta-analysis. *Fam Med* **37**: 506–512.

Tseng CH (2011) Diabetes and risk of prostate cancer: a study using the National Health Insurance. *Diabetes Care* **34**: 616–621.

van Vuuren SP, Heyns CE, Zarrabi AD (2012) Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate. *BJU Int* **109**: 1194–1197.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.